GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Notes Receivable

Centessa Pharmaceuticals (STU:260) Notes Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Notes Receivable?

Centessa Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Centessa Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Centessa Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Notes Receivable Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Centessa Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Centessa Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (STU:260) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines